| pubmed-article:7871905 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7871905 | lifeskim:mentions | umls-concept:C0016053 | lld:lifeskim |
| pubmed-article:7871905 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7871905 | lifeskim:mentions | umls-concept:C0295352 | lld:lifeskim |
| pubmed-article:7871905 | lifeskim:mentions | umls-concept:C1314792 | lld:lifeskim |
| pubmed-article:7871905 | lifeskim:mentions | umls-concept:C0205246 | lld:lifeskim |
| pubmed-article:7871905 | lifeskim:mentions | umls-concept:C0332206 | lld:lifeskim |
| pubmed-article:7871905 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:7871905 | pubmed:dateCreated | 1995-3-28 | lld:pubmed |
| pubmed-article:7871905 | pubmed:abstractText | In more than 40% of patients with fibromyalgia a marked influence on the pain in the skeletal system with a decrease of the tenderness at "tenderpoints" can be achieved by blocking the 5-HT3-receptors with ondansetron or tropisetron-hydrochloride. Physical complaints and vegetative signs also improve. It is discussed if patients not responding to therapy with ondansetron or tropisetron-hydrochloride have to be discriminated as a subgroup of fibromyalgia. More investigations are needed to confirm the described effects. | lld:pubmed |
| pubmed-article:7871905 | pubmed:language | ger | lld:pubmed |
| pubmed-article:7871905 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7871905 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7871905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7871905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7871905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7871905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7871905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7871905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7871905 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7871905 | pubmed:issn | 0340-1855 | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:MüllerWW | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:SchweigerCC | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:StrateCC | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:MennetPP | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:HrycajPP | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:FärberLL | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:LacksPP | lld:pubmed |
| pubmed-article:7871905 | pubmed:author | pubmed-author:SchochatTT | lld:pubmed |
| pubmed-article:7871905 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7871905 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:7871905 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7871905 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7871905 | pubmed:pagination | 335-8 | lld:pubmed |
| pubmed-article:7871905 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:meshHeading | pubmed-meshheading:7871905-... | lld:pubmed |
| pubmed-article:7871905 | pubmed:articleTitle | [Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors]. | lld:pubmed |
| pubmed-article:7871905 | pubmed:affiliation | Hochrhein-Institut für Rehabilitationsforschung, Bad Säckingen. | lld:pubmed |
| pubmed-article:7871905 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7871905 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7871905 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:7871905 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
